Table 3.

Subgroup analysis of the correlation between PNI and progression-free survival.

Subgroup	No. of studies	PFS hazard ratios (95% CI)	p-value	Heterogeneity
				I 2	p -value
Region
Asia	8	1.80 (1.35–2.40)	< 0.001	38.70%	0.121
No-Asia	2	2.14 (1.41–3.24)	< 0.001	25.30%	0.247
Age group
≤ 65	2	2.35 (1.69–3.28)	< 0.001	0.00%	0.326
>65	7	1.67 (1.27–2.21)	< 0.001	27.00%	0.222
Cut-off value
≤ 45.05	7	1.71 (1.29–2.26)	< 0.001	27.90%	0.215
>45.05	3	2.34 (1.67–3.27)	< 0.001	17.70%	0.297
Therapy type
ICI	5	1.60 (1.02–2.52)	0.041	57.40%	0.052
PD-1	3	1.51(0.86–2.65)	0.153	61.90%	0.072
Combination	5	2.14 (1.67–2.73)	< 0.001	0.00%	0.657

PD-1, programmed cell death protein-1; CI, confidence interval; ICI, immune checkpoint inhibitor.